Treatment of Juvenile Absence Epilepsy in Children Under 16 Years
Clinical Scenario
This protocol addresses juvenile absence epilepsy specifically in patients younger than 16 years of age — a pediatric population in which treatment selection requires careful attention to age-appropriate considerations.
Patient Population
Children younger than 16 years presenting with juvenile absence epilepsy represent a distinct group where antiepileptic drug choices and dosing strategies must account for the patient's age and any concurrent medications.
Treatment Approach (Summary)
Current evidence supports a monotherapy approach for this patient group — trialling an indicated oral antiepileptic agent before any combination therapy is considered. The specific agent and its dosing are determined in part by the patient's other current antiepileptic drugs. The complete regimen and sequencing are available in the full structured protocol.
References
- Children (younger than 16 years)
- Monotherapy with all indicated AEDs should be attempted before initiating combination therapy.
- Level C: lamotrigine
- Specific dosing recommendations depend on other current antiepileptic drugs
View source ↗